Cel During the past few years tremendous efforts have been made to identify and characterise a very rare cell, the human haematopoietic stem cell. This cell is defined by two criteria, its ability to self-renew and its ability to give rise to all lineages of blood cells throughout an entire lifespan. Many diseases of the blood system arise as a consequence of either germ-line or somatic mutations in genes involved in controlling cell differentiation and survival. Inherited blood diseases, such as the lysosomal storage diseases, severe combined immunodeficiencies and thalassaemias, have their basis in gene alterations related to lineage specific development. Neoplastic transformation of haemopoietic stem/ progenitor cells (eg. in the leukaemias and lymphomas) is characterised by somatic mutations in genes crucial to regulatory developmental processes, such as ectopic receptor expression (eg. growth factor and retinoic acid receptors) and inappropriate timing of protein synthesis encoded by developmental control genes (eg. homeobox genes, bcl2). Gene therapy is potentially the most appropriate treatment for such diseases. However, technological advances in manipulating genetic material for gene transfer protocols require a detailed understanding of: (i) the biology of haematopoietic stem cells and their lineage restricted progeny (ie. self-renewal and differentiation potential, cell cycle controls, cell surface receptors, ex vivo expansion, transplantation ability); (ii) gene expression and regulation in progenitor/stem cell subsets; and (iii) the development of gene transfer protocols into isolated haematopoietic stem cells using viral and non-viral vectors. The present European concerted action is investigating each of these aspects. The Central and Eastern European Laboratories will contribute to these studies by identifying and cloning stem cell surface receptors (the MRF molecule and the production of specific CDNA libraries), by studies on the introduction of DNA repair and adenosine deaminase (ADA) genes into murine and human haematopoietic stem cells, by studies on the isolation, ex vivo expansion and Go controls of isolated haematopoietic stem cells, and by studying the feasibility of developing haematopoietic stem cell banks in these countries. Program(-y) IC-PECO/COPERNICUS - Scientific and technological cooperation between the European Community and European non-member countries, 1992- Temat(-y) 0201 - CEEC participation in BIOMEDICAL AND HEALTH RESEARCH programme Zaproszenie do składania wniosków Data not available System finansowania CSC - Cost-sharing contracts Koordynator The Chancellor, Masters and Scholars of the University of Oxford Wkład UE Brak danych Adres John Radcliffe Hospital Headington OX3 9DU Oxford Zjednoczone Królestwo Zobacz na mapie Koszt całkowity Brak danych Uczestnicy (3) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko Engelhardt Institute of Molecular Biology - Russian Academy of Sciences Rosja Wkład UE Brak danych Adres 32,Vavilov Str. 117984 Moskva B334 Zobacz na mapie Koszt całkowity Brak danych Military Institute of Hygiene and Epidemiology Polska Wkład UE Brak danych Adres 4,Kozielska 01 163 Warszawa Zobacz na mapie Koszt całkowity Brak danych The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology Polska Wkład UE Brak danych Adres 15,Wawelska 00 973 Warszana Zobacz na mapie Koszt całkowity Brak danych
